The influence of hyperhydration on pemetrexed concetrations in blood.
Recruiting
- Conditions
- non-small cell lung cancer, NSCLC, mesothelioma
- Registration Number
- NL-OMON21433
- Lead Sponsor
- ZANOB pharmacy/Jeroen Bosch Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 15
Inclusion Criteria
1. At least 18 years old
2. Planned for treatment with cisplatin/pemetrexed combination therapy followed by pemetrexed maintenance therapy as a part of routine care.
Exclusion Criteria
Patients that suffer from conditions that affect hemostasis in a way that blood drawing is complicated
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary endpoint is the observed difference in the pharmacokinetics of pemetrexed when administered with or without hyperhydration.
- Secondary Outcome Measures
Name Time Method The secondary endpoint of our study is to screen whether novel renal function algorithms (CKD-EPI) outperform the classically used Cockroft-Gault algorithm to predict pemetrexed pharmacokinetics